CStone and Bayer to trial CS1001 with regorafenib in multiple cancers
Chinese biotech firm CStone Pharmaceuticals (HKEX: 2616) today announced that the company has entered into a global clinical collaboration with China focus with Bayer HealthCare LLC, a unit of Germany’s Bayer (BAYN: DE)
The companies will evaluate the safety, tolerability, pharmacokinetics (PK) and antitumor activity of its PD-L1 monoclonal antibody CS1001, the Chinese firm’s lead candidate, in combination with Bayer's Stivarga (regorafenib), an oral multi-kinase inhibitor (targeting VEGFR, FGFR, CSF1R, etc), as a treatment for multiple cancers including gastric cancer. This is the first global proof-of-concept study carried out as a collaboration between the two companies. CStone will be the study sponsor and Bayer will provide regorafenib throughout the clinical trial program.
No financial terms of the collaboration were revealed, but CStone’ shares closed the day up 3.63% at HK$12.56, while Bayer was unchanged due to a public holiday in Germany.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze